Aclacinomycin A hydrochloride |
| Catalog No.GC35238 |
아클라시노마이신 A 염산염(아클라루비신 염산염)은 형광 분자이며 20S 프로테아좀의 CTRL(키모트립신 유사) 활성에 대해 별개의 특이성을 나타내는 최초의 비펩타이드성 억제제입니다. 아클라시노마이신 A 염산염은 또한 토포이소머라제 I 및 II의 이중 억제제입니다. 혈액암 및 고형 종양에 효과적인 안트라사이클린 화학요법제.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 75443-99-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Aclacinomycin A hydrochloride (Aclarubicin hydrochloride), a fluorescent molecule and the first described non-peptidic inhibitor showing discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome[1]. Aclacinomycin A hydrochloride is also a dual inhibitor of topoisomerase I and II[2]. An effective anthracycline chemotherapeutic agent for hematologic cancers and solid tumors[3]. 20S proteasome[1].Topoisomerase I and II[2].
[1]. Isoe T, et al. Inhibition of different steps of the ubiquitin system by CDDP and aclarubicin. Biochim Biophys Acta. 1992 Sep 15;1117(2):131-5. [2]. Hajji N, et al. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583(1):26-35. [3]. Iihoshi H, et al. Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells. Toxicol Lett. 2017 Aug 5;277:109-114.
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *